
Genaera Corporation (Nasdaq: GENR) reported data from its second Phase 1 clinical trial of trodusquemine (MSI-1436), Genaera's lead drug candidate for the treatment of type 2 diabetes and obesity. MSI-1436 is a novel inhibitor of PTP1B, a validated molecular target that controls the function of both the leptin and insulin pathways to normalize glucose and decrease appetite.
Click here for full Story http://www.medicalnewstoday.com/articles/124392.php |